Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05518812 · ClinicalTrials.gov registry record · Early Phase 1
Carboprost (Hemabate) for Fibroid Resection
A Early Phase 1 study, sponsored by Northwestern University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 19
- Enrollment target
NCT05518812 is a Early Phase 1 study that has completed, run by Northwestern University. The registered enrollment target is 19 participants.
The verdict
NCT05518812, a Early Phase 1 study, has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 19 participants
- Enrollment target
Study Summary
The purpose of this research study is to determine if low-dose (i.e., a fraction of what is commonly used) carboprost (Hemabate) helps facilitate fibroid removal (myomectomy).
Interventions
- DRUG Carboprost Tromethamine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2022-07-12 |
| Est. Completion | 2024-05-06 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05518812
The ClinicalTrials.gov registry entry for NCT05518812 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Carboprost Tromethamine is the first listed.
NCT05518812 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05518812 about?
NCT05518812 is a clinical study titled "Carboprost (Hemabate) for Fibroid Resection". The purpose of this research study is to determine if low-dose (i.e., a fraction of what is commonly used) carboprost (Hemabate) helps facilitate fibroid removal (myomectomy).
What is the current status of trial NCT05518812?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 19 participants. The study started on 2022-07-12. Estimated completion is 2024-05-06.
What interventions are being tested in trial NCT05518812?
The interventions under investigation include: Carboprost Tromethamine (DRUG).
Who is sponsoring clinical trial NCT05518812?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.